Updating results

1127 results

Sort: Relevance | Date

Tests in secondary care to identify people at high risk of ovarian cancer (DG31)

Evidence-based recommendations on tests (IOTA ADNEX, Overa, RMI I, ROMA, IOTA Simple Rules) in secondary care to identify people at high risk of ovarian cancer

Diagnostics guidance Published November 2017

Lead-I ECG devices for detecting symptomatic atrial fibrillation using single time point testing in primary care (DG35)

Evidence-based recommendations on lead-I ECG devices for detecting symptomatic atrial fibrillation using single time point testing in primary care

Diagnostics guidance Published May 2019

Intraoperative tests (RD‑100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer (DG8)

Evidence-based recommendations on the RD-100i OSNA system and Metasin test for detecting sentinel lymph node metastases in breast cancer

Diagnostics guidance Published August 2013

EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer (DG9)

Evidence-based recommendations on EGFR-TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer (NSCLC)

Diagnostics guidance Published August 2013

Detecting, managing and monitoring haemostasis: viscoelastometric point‑of‑care testing (ROTEM, TEG and Sonoclot systems) (DG13)

Evidence-based recommendations on viscoelastometric point-of-care testing (ROTEM, TEG and Sonoclot systems) to detect, manage and monitor haemostasis

Diagnostics guidance Published August 2014

Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (DG16)

Evidence-based recommendations on the My5-FU assay for guiding dose adjustment for fluorouracil chemotherapy

Diagnostics guidance Published December 2014

High-sensitivity troponin for the early rule out of acute myocardial infarction

In development [GID-DG10035] Expected publication date: 26 August 2020

Diagnostics guidance In development

PredictSURE-IBD and IBDX to guide personalised treatment of Crohn's disease

In development [GID-DG10029] Expected publication date: 08 July 2020

Diagnostics guidance In development

Testing strategies for Lynch syndrome in people with endometrial cancer

In development [GID-DG10033] Expected publication date: 29 July 2020

Diagnostics guidance In development

QAngio XA 3D/ QFR and CAAS vFFR imaging software for assessing the functional significance of coronary obstructions during invasive coronary angiography

In development [GID-DG10034] Expected publication date: 30 September 2020

Diagnostics guidance In development

Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke

In development [GID-DG10023] Expected publication date: TBC

Diagnostics guidance In development

Xpert MTB/RIF assay for the detection of active pulmonary tuberculosis and multi-drug resistant tuberculosis

In development [GID-DT9] Expected publication date: TBC

Diagnostics guidance In development

KRAS mutation testing of tumours in adults with metastatic colorectal cancer (discontinued)

In development [GID-DT14] Expected publication date: TBC

Diagnostics guidance In development

Diagnosing prostate cancer: PROGENSA PCA3 assay and Prostate Health Index (DG17)

This guideline has been updated and replaced by NICE guideline NG131.

Diagnostics guidance Published June 2015

Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia (DG2)

Both index tests included in this guidance are no longer commercially available. Therefore the guidance has been withdrawn.

Diagnostics guidance Published December 2011

Guidance on the use of trastuzumab for the treatment of advanced breast cancer (TA34)

Evidence-based recommendations on the use of trastuzumab (Herceptin) for the treatment of advanced breast cancer

Technology appraisal guidance Published March 2002

Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal) (TA334)

NICE is unable to make recommendations about regorafenib for metastatic colorectal cancer because no evidence submission was received from Bayer for the..

Technology appraisal guidance Published February 2015

Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) (TA23)

Evidence-based recommendations on temozolomide (Temodal) for malignant glioma in children over 3 years, young people and adults.

Technology appraisal guidance Published April 2001 Last updated March 2016

Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA217)

Evidence-based recommendations on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (Ebixa) for treating Alzheimer's disease

Technology appraisal guidance Published March 2011 Last updated June 2018

Decitabine for the treatment of acute myeloid leukaemia (terminated appraisal) (TA270)

NICE is unable to make a recommendation about the use in the NHS of decitabine for the treatment of acute myeloid leukaemia because no evidence...

Technology appraisal guidance Published December 2012

Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia (TA29)

Evidence-based recommendations on the use of fludarabine for B-cell chronic lymphocytic leukaemia (CLL)

Technology appraisal guidance Published September 2001

Canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks (terminated appraisal) (TA281)

NICE is unable to recommend the use in the NHS of canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks

Technology appraisal guidance Published April 2013

Pharmalgen for the treatment of bee and wasp venom allergy (TA246)

Evidence-based recommendations on Pharmalgen (ALK-Abelló) for treating bee and wasp venom allergy

Technology appraisal guidance Published February 2012

Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 (TA257)

Evidence-based recommendations on lapatinib (Tyverb) or trastuzumab (Herceptin) combined with an aromatase inhibitor for the first-line treatment of..

Technology appraisal guidance Published June 2012

Omalizumab for treating severe persistent allergic asthma (TA278)

Evidence-based recommendations on omalizumab (Xolair) for treating severe persistent allergic asthma

Technology appraisal guidance Published April 2013

Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal) (TA273)

NICE is unable to make a recommendation about the use in the NHS of tadalafil for treating symptoms associated with benign prostatic hyperplasia...

Technology appraisal guidance Published January 2013

Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza (TA158)

Evidence-based recommendations on oseltamivir (Tamiflu), amantadine (Lysovir, Symmetrel) and zanamivir (Relenza) to prevent influenza (flu)

Technology appraisal guidance Published September 2008

Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (TA155)

Evidence-based recommendations on ranibizumab (Lucentis) and pegaptanib (Macugen) for the treatment of age-related macular degeneration (AMD)

Technology appraisal guidance Published August 2008 Last updated May 2012

Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women (TA160)

Evidence-based recommendations on raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women

Technology appraisal guidance Published October 2008 Last updated February 2018

Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin (TA159)

Evidence-based recommendations on spinal cord stimulation (SCS) for chronic pain of neuropathic or ischaemic origin in adults

Technology appraisal guidance Published October 2008

Structural neuroimaging in first-episode psychosis (TA136)

Evidence-based recommendations on structural neuroimaging for treating first-episode psychosis

Technology appraisal guidance Published February 2008

Pemetrexed for the treatment of malignant pleural mesothelioma (TA135)

Evidence-based recommendations on pemetrexed (Alimta) for treating malignant pleural mesothelioma (cancer)

Technology appraisal guidance Published January 2008

Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years (TA131)

Evidence-based recommendations on inhaled corticosteroids (ICSs) for chronic asthma in children aged under 12

Technology appraisal guidance Published November 2007

Docetaxel for the treatment of hormone-refractory metastatic prostate cancer (TA101)

Evidence-based recommendations on docetaxel (Taxotere) for the treatment of hormone-refractory metastatic (advanced) prostate cancer

Technology appraisal guidance Published June 2006

Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer (TA100)

Evidence-based recommendations on capecitabine (Xeloda) and oxaliplatin (Eloxatin) for adjuvant treatment of stage III (Dukes' C) colon (bowel) cancer

Technology appraisal guidance Published April 2006

Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma (TA10)

Evidence-based recommendations on the use of inhaler systems (devices) for chronic asthma in children under 5

Technology appraisal guidance Published August 2000

Guidance on the Extraction of Wisdom Teeth (TA1)

Evidence-based recommendations on the extraction of wisdom teeth

Technology appraisal guidance Published March 2000

Methadone and buprenorphine for the management of opioid dependence (TA114)

Evidence-based recommendations on methadone and buprenorphine for the management of opioid dependence

Technology appraisal guidance Published January 2007

Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma (TA121)

Evidence-based recommendations on carmustine implants Gliadel) and temozolomide (Temodal) for newly diagnosed high-grade glioma (brain tumour)

Technology appraisal guidance Published June 2007

Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy (TA117)

Evidence-based recommendations on cinacalcet (Mimpara) for treating secondary hyperparathyroidism to treat people on dialysis who have kidney disease

Technology appraisal guidance Published January 2007

Naltrexone for the management of opioid dependence (TA115)

Evidence-based recommendations on naltrexone (Nalorex) for the management of opioid dependence

Technology appraisal guidance Published January 2007

Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C (TA106)

Evidence-based recommendations on peginterferon alfa (Pegasys) and ribavirin (Copegus) for treating mild chronic hepatitis C

Technology appraisal guidance Published August 2006 Last updated November 2013

Amantadine, oseltamivir and zanamivir for the treatment of influenza (TA168)

Evidence-based recommendations on amantadine (Lysovir, Symmetrel), oseltamivir (Tamiflu) and zanamivir (Relenza) for treating influenza (flu)

Technology appraisal guidance Published February 2009

Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (TA151)

Evidence-based recommendations on continuous subcutaneous insulin infusion for the treatment of diabetes mellitus

Technology appraisal guidance Published July 2008

Carmustine implants for the treatment of recurrent glioblastoma multiforme (terminated appraisal) (TA149)

NICE is unable to make a recommendation about the use in the NHS of carmustine implants because no evidence submission was received from the

Technology appraisal guidance Published June 2008

Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal) (TA148)

NICE is unable to make a recommendation about the use in the NHS of bevacizumab for treating non-small-cell lung cancer (NSCLC)

Technology appraisal guidance Published June 2008